News
31m
India Today on MSNUS FDA rejects GSK's blood cancer drug over safety, limited treatment benefitGSK’s attempt to relaunch Blenrep was blocked by FDA advisers due to poor clinical benefit, safety concerns, and eye-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results